Molecular Partners AG (MOLN)
3.98
+0.22
(+5.71%)
USD |
NASDAQ |
May 03, 16:00
4.17
+0.19
(+4.77%)
After-Hours: 20:00
Molecular Partners Cash from Financing (TTM): -1.300M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.300M |
| September 30, 2023 | -1.313M |
| June 30, 2023 | -1.920M |
| March 31, 2023 | -1.891M |
| December 31, 2022 | -1.646M |
| Date | Value |
|---|---|
| September 30, 2022 | -1.317M |
| June 30, 2022 | -2.128M |
| March 31, 2022 | 55.54M |
| December 31, 2021 | 55.34M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.128M
Minimum
Jun 2022
55.54M
Maximum
Mar 2022
11.04M
Average
-1.317M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
| AC Immune SA | 48.17M |
| CRISPR Therapeutics AG | 62.66M |
| Addex Therapeutics Ltd | 5.863M |
| NLS Pharmaceutics Ltd | 13.81M |
| MoonLake Immunotherapeutics | 479.70M |